OptimizeRx (NASDAQ:OPRX – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Analyst Ratings
This is a summary of current ratings and price targets for OptimizeRx and Aclarion, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OptimizeRx | 1 | 2 | 6 | 0 | 2.56 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
OptimizeRx currently has a consensus target price of $11.43, indicating a potential upside of 56.77%. Aclarion has a consensus target price of $7.50, indicating a potential upside of 188.46%. Given Aclarion’s higher probable upside, analysts plainly believe Aclarion is more favorable than OptimizeRx.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OptimizeRx | $109.43 million | 1.26 | $5.13 million | $0.23 | 31.70 |
| Aclarion | $80,000.00 | 93.60 | -$7.23 million | ($7.40) | -0.35 |
OptimizeRx has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares OptimizeRx and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OptimizeRx | 4.66% | 9.44% | 7.11% |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
Risk and Volatility
OptimizeRx has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Institutional & Insider Ownership
76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 7.5% of OptimizeRx shares are held by company insiders. Comparatively, 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
OptimizeRx beats Aclarion on 11 of the 14 factors compared between the two stocks.
About OptimizeRx
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
